
Phase 3 trial of epcoritamab in relapsed/refractory DLBCL misses primary overall survival endpoint in U.S.
Genmab and AbbVie announced that the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a bispecific antibody treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), did not meet its primary endpoint of overall survival (OS) in ...


